"Patients
This retrospective study included all patients, who have been referred to the Department of Nuclear Medicine, Medical University of Vienna, Vienna General Hospital, between September 2015 and September 2018 for receiving PSMA-RLT due to mCRPC. The median duration of follow-up for patients included in this study was 24 months and ranged between 6 and 40 months."
"in patients with an advanced metastatic castration-resistant prostate cancer (mCRPC)"
https://link.springer.com/article/10.1007/s00259-019-04584-1
Disclaimer I have a very biased views about NOX because after 5 years they still have no granted IP with a failed drug that lapsed it 20 year granted status years ago.
"Patients This retrospective study included all patients, who...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.5¢ | $15.88K | 144.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45861 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 60156 | 2 |
View Market Depth
| Last trade - 13.04pm 18/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |